<DOC>
	<DOCNO>NCT01164696</DOCNO>
	<brief_summary>The objective study compare hematological toxicity , cost , health-related quality Life ( HR-QOL ) outcomes observed real life Belgian Non-Hodgkin Lymphoma ( NHL ) population receive 90Y-Zevalin , model-predicted data reimbursement basis clinical trial heavily pre-treated NHL .</brief_summary>
	<brief_title>A Prospective Observational Study Evaluate Quality Life Costs Real Life Setting Patients Who Are Treated With 90Y-Zevalin</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Advanced cancer lymph node follicular type study inclusion The patient relapse refractory disease , previous treatment rituximab Treating physician decide treat patient 90YZevalin regimen The patient &gt; = 18 year age Patient give informed consent Patient unwilling unable give inform consent Patient participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Quality Life , Health Care Costs</keyword>
</DOC>